Randomised clinical trial: The effect of baclofen in patients with gastro-oesophageal reflux - A randomised prospective study

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 9, 2012, Pages 1036-1044

  Cossentino, M J ^a   Mann, K ^a   Armbruster, S P ^a   Lake, J M ^a   Maydonovitch, C ^a   Wong, R K H ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; MYLANTA; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGUS MANOMETRY; FEMALE; GASTRIC PH MONITORING; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STOMACH PARAMETERS; STOMACH PH; SYMPTOMATOLOGY; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; BACLOFEN; CHEST PAIN; DOUBLE-BLIND METHOD; ERUCTATION; ESOPHAGEAL PH MONITORING; FEMALE; GABA-B RECEPTOR AGONISTS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MANOMETRY; MIDDLE AGED; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875706659     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05068.x     Document Type: Article

References (32)

1. Dent J, El-Sarag HB, Wallander MA, Johansson S. Epidemiology of gastrooesophageal reflux disease; a systematic review. Gut 2005; 54: 710-7.
2. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease- where next? Aliment Pharmacol Ther 2005; 22: 79-94.
3. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980; 65: 256-67.
4. Dent J, Holloway RH, Toouli J, Dodds WJ. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut 1988; 29: 1020-8.
5. Mittal RK, McCallum RW. Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis. Gastroenterology 1988; 95: 593-9.
6. McDermott CM, Abrahams TP, Partosoedarso E, et al. Site of action of GABA(B) receptor for vagal motor control of the lower esophageal sphincter in ferrets and rats. Gastroenterology 2001; 120: 1749-62.
7. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. Control of transient lower esophageal sphincter relaxations and reflux by the GABA (B) agonist baclofen in normal subjects. Gastroenterology 2000; 118: 7-13.
8. Lehmann A, Antonsson M, Bremner- Danielsen M, Flardh M, Hansson- Branden L, Karrberg L. Activation of the GABA (B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999; 117: 1147-54.
9. Staunton E, Smid SD, Dent J, Blackshaw LA. Triggering of transient LES relaxations in ferrets: role of sympathetic pathways and effects of baclofen. Am J Physiol Gastrointest Liver Physiol 2000; 279: G157-62.
10. Lehmann A, Hansson-Branden L, Karrberg L. Effects of repeated administration of baclofen on transient lower esophageal sphincter relaxation in the dog. Eur J Pharmacol 2000; 403: 163-7.
11. Blackshaw LA, Staunton E, Lehmann A, Dent J. Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol 1999; 277: G867-74.
12. Van Herwaarden MA, Samsom M, Rydholm H, Smout AJ. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002; 16: 1655-62.
13. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and nonacid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17: 243-51.
14. Cange L, Johnsson E, Rydholm H, et al. Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. Aliment Pharmacol Ther 2002; 16: 869-73.
15. Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastrooesophageal reflux disease. Gut 2003; 52: 464-70.
16. Omari TI, Benninga MA, Sansom L, Butler RN, Dent J, Davidson GP. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr 2006; 149: 468-74.
17. Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA (B) agonist baclofen in patients with gastrooesophageal reflux disease. Gut 2002; 50: 19-24.
18. Gerson LB, Huff FJ, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2010; 105: 1266-75.
19. Nimish B, Vakil N, Huff J, et al. Arbaclofen placarbil monotherapy decreases GERD symptoms in subjects with previous PPI therapy. Gastroenterology 2009; 136: A79.
20. Vakil NB, Huff FJ, Bian A, Jones DS, Stamler D. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2011; 106: 1427-38.
21. Blondeau R. Treatment of gastroesophageal reflux disease: the new kids to block. Neurogastroenterol Motil 2010; 22: 836-40.
22. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
23. Wilson KG, Graham ID, Viola RA, et al. Structured interview assessment of symptoms and concerns in palliative care. Can J Psychiatry 2004; 49: 350-8.
24. Johnson LF, Demeester TR. Twentyfour- hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974; 62: 325-32.
25. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397-402.
26. Cremonini F, Ziogas DC, Chang HY, et al. Meta-analysis: the effects of placebo treatment on gastrooesophageal reflux disease. Aliment Pharmacol Ther 2010; 32: 29-42.
27. Tack J. Is there a unifying role for visceral hypersensitivity and irritable bowel syndrome in non-erosive reflux disease? Digestion 2008; 78(Suppl. 1): 42-5.
28. Blondeau K, Boeckxstaens V, Rommel N, et al. Baclofen improves symptoms and reduces postprandial flow events in patients with rumination and supragastric belching. Clin Gastroenterol Hepatol 2011 [Epub ahead of print].
29. Beaumont H, Boeckxstaens G. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy? Am J Gastroenterol 2009; 104: 1764-71.
30. Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010; 139: 409-17.
31. Boeckxstaens GE, Beaumont H, Hatlebackk JG, et al. A novel reflux inhibitor lesogaberan (AZD3355) as add-one treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomized placebo-controlled trial. Gut 2011; 60: 1182-8.
32. Shaheen NJ, Denison H, Bjorck K, Karlsson M, Silberg D. Efficacy of a novel gamma-aminobutyric acid type B receptor (GABAB) agonist, lesogaberan, as an add-on to proton pump inhibitor (PPI) therapy in the treatment of gastroesophageal reflux disease in patients who have a partial response to PPI therapy. Gastoenterology 2011; 140 (Suppl. 1): S578.